{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T23:36:07Z","timestamp":1768260967104,"version":"3.49.0"},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"General Medical Research Project of Jiangsu Provincial Health Commission","award":["No. H2023035"],"award-info":[{"award-number":["No. H2023035"]}]},{"name":"Major Basic Research Project of the Natural Science Foundation of Jiangsu Higher Education Institutions","award":["No. 23KJA320010"],"award-info":[{"award-number":["No. 23KJA320010"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Synflorix is a conjugate vaccine targeting Streptococcus pneumoniae, effectively reducing pneumonia and invasive pneumococcal disease in children under five. To evaluate its safety profile, this study analyzed adverse event (AE) reports associated with Synflorix vaccination submitted to the Vaccine Adverse Event Reporting System (VAERS) from 2010 to 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective analysis of 1,704 VAERS reports from January 1, 2010, to December 30, 2024. Data processing and statistical analysis were performed using R software. Reporting Odds Ratios (ROR) with 95% confidence intervals (CI)\u00a0were calculated to identify potential safety signals. Symptom types, onset times, and severity differences across age groups were examined. To facilitate comparison with other vaccines in the VAERS database, certain Preferred Terms (PTs) were normalized per 100,000 reports.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The most common adverse reactions included crying, pyrexia, hypotonic-hyporesponsive episodes (HHE), pallor, and diarrhea. Newly detected signals not previously listed in the product insert were HHE, hypotonia, pallor, and bronchiolitis. Severe reactions such as pyrexia, crying, vomiting, and pallor showed delayed onset compared to non-severe cases. Infants and toddlers demonstrated stronger systemic reactions within one day post-vaccination, while children aged 2\u201310 years mostly developed injection site nodules. Adults predominantly experienced localized reactions within 10 days. Reports for elderly individuals (\u226555 years) were limited and primarily described mild symptoms like erythema and pyrexia. When compared to other pneumococcal vaccines (PCV7, PCV13, PCV15, PCV20, PPSV23), Synflorix showed the third-highest frequency of mortality and significantly higher RORs\u00a0for HHE, hypotonia, pallor, and bronchiolitis. Additionally, in terms of the timing of AEs, Synflorix exhibited a similar trend to these vaccines, with reactions primarily occurring in the short-term post-vaccination period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Age-specific patterns of adverse events following Synflorix vaccination were observed, with infants and toddlers showing higher intensities of systemic reactions. Compared to other pneumococcal vaccines, Synflorix exhibited a relative higher mortality reporting frequency, along with higher frequencies and RORs for specific PTs, including HHE, hypotonia, pallor, and bronchiolitis. Enhanced post-vaccination monitoring is recommended for younger populations due to their immature immune systems. Age-stratified surveillance can help optimize vaccine safety and management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0338640","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T18:46:02Z","timestamp":1768243562000},"page":"e0338640","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adverse events following Synflorix vaccination reported to the Vaccine Adverse Event Reporting System (VAERS), 2010\u20132024"],"prefix":"10.1371","volume":"21","author":[{"given":"Lingyun","family":"Cui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nian","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8641-3743","authenticated-orcid":true,"given":"Sicong","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"issue":"34","key":"pone.0338640.ref001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/YWHA3079","article-title":"Immunogenicity and seroefficacy of pneumococcal conjugate vaccines: a systematic review and network meta-analysis","volume":"28","author":"S Feng","year":"2024","journal-title":"Health Technol Assess"},{"issue":"4","key":"pone.0338640.ref002","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S1473-3099(24)00588-7","article-title":"Serotype distribution of remaining invasive pneumococcal disease after extensive use of ten-valent and 13-valent pneumococcal conjugate vaccines (the PSERENADE project): a global surveillance analysis","volume":"25","author":"M Garcia Quesada","year":"2025","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"pone.0338640.ref003","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40272-014-0089-x","article-title":"10-Valent pneumococcal non-typeable haemophilus influenzae protein D-conjugate vaccine: a review in infants and children","volume":"16","author":"GL Plosker","year":"2014","journal-title":"Paediatr Drugs"},{"issue":"5","key":"pone.0338640.ref004","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2165\/11202760-000000000-00000","article-title":"Pneumococcal polysaccharide protein D-conjugate vaccine (Synflorix; PHiD-CV)","volume":"11","author":"JD Croxtall","year":"2009","journal-title":"Paediatr Drugs"},{"key":"pone.0338640.ref005","doi-asserted-by":"crossref","first-page":"111776","DOI":"10.1016\/j.ijporl.2023.111776","article-title":"Otitis media at 6-monthly assessments of Australian First Nations children between ages 12-36 months: Findings from two randomised controlled trials of combined pneumococcal conjugate vaccines","volume":"175","author":"AJ Leach","year":"2023","journal-title":"Int J Pediatr Otorhinolaryngol"},{"issue":"6","key":"pone.0338640.ref006","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S2213-2600(14)70060-8","article-title":"Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study","volume":"2","author":"CMAS Domingues","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"3","key":"pone.0338640.ref007","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s40258-018-0387-5","article-title":"A cost-effectiveness analysis of the 10-valent pneumococcal non-typeable haemophilus influenzae protein D CONJUGATE VACCINE (PHiD-CV) compared to the 13-valent pneumococcal conjugate vaccine (PCV13) for universal mass vaccination implementation in New Zealand","volume":"16","author":"L Varghese","year":"2018","journal-title":"Appl Health Econ Health Policy"},{"issue":"7","key":"pone.0338640.ref008","doi-asserted-by":"crossref","first-page":"2135916","DOI":"10.1080\/21645515.2022.2135916","article-title":"Estimated public health impact of human rotavirus vaccine (HRV) and pneumococcal polysaccharide protein D-conjugate vaccine (PHiD-CV) on child morbidity and mortality in Gavi-supported countries","volume":"18","author":"A Marijam","year":"2022","journal-title":"Hum Vaccin Immunother"},{"issue":"10","key":"pone.0338640.ref009","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1080\/21645515.2017.1343773","article-title":"Overall effectiveness of pneumococcal conjugate vaccines: An economic analysis of PHiD-CV and PCV-13 in the immunization of infants in Italy","volume":"13","author":"P Castiglia","year":"2017","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"pone.0338640.ref010","doi-asserted-by":"crossref","first-page":"732","DOI":"10.3390\/pathogens12050732","article-title":"Systematic review and meta-analysis of the efficacy and effectiveness of pneumococcal vaccines in adults","volume":"12","author":"JL Farrar","year":"2023","journal-title":"Pathogens"},{"issue":"1","key":"pone.0338640.ref011","doi-asserted-by":"crossref","first-page":"6022","DOI":"10.1038\/s41598-025-90135-8","article-title":"A real-world pharmacovigilance analysis of hepatitis B vaccine using the U.S. Vaccine Adverse Event Reporting System (VAERS) database","volume":"15","author":"H Zhou","year":"2025","journal-title":"Sci Rep"},{"issue":"3","key":"pone.0338640.ref012","doi-asserted-by":"crossref","DOI":"10.1002\/ski2.367","article-title":"Exploring cutaneous lymphoproliferative disorders in the wake of COVID-19 vaccination","volume":"4","author":"ER Gordon","year":"2024","journal-title":"Skin Health Dis"},{"issue":"26","key":"pone.0338640.ref013","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1016\/j.vaccine.2016.03.107","article-title":"Status of research and development of pediatric vaccines for Streptococcus pneumoniae","volume":"34","author":"MR Alderson","year":"2016","journal-title":"Vaccine"},{"issue":"40","key":"pone.0338640.ref014","doi-asserted-by":"crossref","first-page":"6291","DOI":"10.1016\/j.vaccine.2020.07.039","article-title":"Adverse events following quadrivalent meningococcal diphtheria toxoid conjugate vaccine (Menactra\u00ae) reported to the Vaccine Adverse Event Reporting System (VAERS), 2005-2016","volume":"38","author":"TR Myers","year":"2020","journal-title":"Vaccine"},{"issue":"3","key":"pone.0338640.ref015","first-page":"353","article-title":"VAERS vasculitis adverse events retrospective study: etiology model of immune complexes activating fc receptors in kawasaki disease and multisystem inflammatory syndromes","volume":"14","author":"DO Ricke","year":"2024","journal-title":"Life (Basel)"},{"issue":"4","key":"pone.0338640.ref016","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1080\/09286586.2024.2399345","article-title":"Retinal Vascular Occlusions After COVID-19 Vaccination in South Korea: A Nation-Wide Population-Based Study","volume":"32","author":"Y Kim","year":"2025","journal-title":"Ophthalmic Epidemiol"},{"key":"pone.0338640.ref017","article-title":"Hypotonic-hyporesponsive episodes reported to the Vaccine Adverse Event Reporting System (VAERS), 1996-1998","volume":"106","author":"DuVernoy TS, Braun MM, the VAERS Working Group","year":"2000","journal-title":"Pediatrics"},{"issue":"8","key":"pone.0338640.ref018","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1080\/14760584.2020.1800458","article-title":"Safety profile of Infanrix hexa - 17 years of GSK\u2019s passive post-marketing surveillance","volume":"19","author":"I Puente G\u00f3mez","year":"2020","journal-title":"Expert Rev Vaccines"},{"issue":"31","key":"pone.0338640.ref019","doi-asserted-by":"crossref","first-page":"5875","DOI":"10.1016\/j.vaccine.2007.04.061","article-title":"Hypotonic-hyporesponsive episode (HHE) as an adverse event following immunization in early childhood: case definition and guidelines for data collection, analysis, and presentation","volume":"25","author":"M Buettcher","year":"2007","journal-title":"Vaccine"},{"issue":"12","key":"pone.0338640.ref020","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1097\/INF.0000000000003308","article-title":"Hypotonic-hyporesponsive Episodes After Diphtheria, Tetanus and Acellular Pertussis Vaccination","volume":"40","author":"J Hansen","year":"2021","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"pone.0338640.ref021","first-page":"771","article-title":"Hypotonic-Hyporesponsive Episode after immunization with whole-cell pertussis combination vaccine. Clinical Case Report","volume":"88","author":"J Velasco","year":"2017","journal-title":"Rev Chil Pediatr"},{"issue":"4","key":"pone.0338640.ref022","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/INF.0b013e318162a127","article-title":"The effect of age and dose number on the risk of collapse (hypotonic-hyporesponsive episode) after pertussis vaccination","volume":"27","author":"PE Vermeer-de Bondt","year":"2008","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"pone.0338640.ref023","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2223\/JPED.1721","article-title":"Incidence of hypotonic-hyporesponsive episodes associated to the combined DTP\/Hib vaccine used in Brazilian National Immunizations Program","volume":"83","author":"RM Martins","year":"2007","journal-title":"J Pediatr (Rio J)"},{"issue":"1","key":"pone.0338640.ref024","doi-asserted-by":"crossref","first-page":"2035141","DOI":"10.1080\/21645515.2022.2035141","article-title":"Surveillance of adverse events following immunization of 13-valent pneumococcal conjugate vaccine among infants, in Zhejiang province, China","volume":"18","author":"Y Hu","year":"2022","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"pone.0338640.ref025","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/jpids\/piad009","article-title":"Increased RSV-A bronchiolitis severity in RSV-infected children admitted to a reference center in Catalonia (Spain) between 2014 and 2018","volume":"12","author":"J Vila","year":"2023","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"3","key":"pone.0338640.ref026","first-page":"165","article-title":"C-reactive protein is associated with severity in hospitalized children with respiratory syncytial virus bronchiolitis","volume":"27","author":"A Adar","year":"2025","journal-title":"Isr Med Assoc J"},{"issue":"3","key":"pone.0338640.ref027","doi-asserted-by":"crossref","DOI":"10.1097\/PCC.0000000000003670","article-title":"Patterns of use of \u03b2-2 agonists, steroids, and mucoactive medications to treat bronchiolitis in the PICU: U.S. Pediatric Health Information System 2009-2022 Database Study","volume":"26","author":"BF Flaherty","year":"2025","journal-title":"Pediatr Crit Care Med"},{"key":"pone.0338640.ref028","doi-asserted-by":"crossref","first-page":"1510948","DOI":"10.3389\/fimmu.2025.1510948","article-title":"Case Report: First report of Legionella micdadei pneumonia and organizing pneumonia in a patient with myelodysplastic and Sweet syndromes","volume":"16","author":"Y Chen","year":"2025","journal-title":"Front Immunol"},{"issue":"12","key":"pone.0338640.ref029","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1080\/21645515.2019.1631134","article-title":"Acute respiratory failure due to eosinophilic pneumonia following pneumococcal vaccination","volume":"15","author":"R Kikuchi","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"pone.0338640.ref030","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkad068","article-title":"Comparison of PCV10, PCV13, PCV15, PCV20 and PPSV23 vaccine coverage of invasive Streptococcus pneumoniae isolate serotypes in Canada: the SAVE study, 2011-20","volume":"78","author":"JJ Schellenberg","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"pone.0338640.ref031","doi-asserted-by":"crossref","first-page":"126931","DOI":"10.1016\/j.vaccine.2025.126931","article-title":"A phase 3 study of 20-valent pneumococcal conjugate vaccine in healthy toddlers previously vaccinated in infancy with 13-valent pneumococcal conjugate vaccine","volume":"53","author":"F Martin\u00f3n-Torres","year":"2025","journal-title":"Vaccine"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0338640","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T18:46:09Z","timestamp":1768243569000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0338640"}},"subtitle":[],"editor":[{"given":"Dominic","family":"Umoru","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0338640","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]}}}